AstraZeneca’s $545m Deal with Pinetree for EGFR Degrader

Gowling WLG advised AstraZeneca on exclusive option and global license agreement with Pinetree Therapeutics.AstraZeneca has entered into an exclusive option and global license agreement with the…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Avatar

Author: Georgio Naffaa

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here